Skip to main content

Tarek M. Mekhail, MD

Tarek M. Mekhail, MD

Medical Director (Thoracic Cancer), Medical Oncologist

Cancer

Tarek Mekhail

Overview

Dr. Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd is board-certified in internal medicine, hematology and oncology. Dr. Mekhail serves as medical director of the Thoracic Cancer Program at the Florida Hospital Cancer Institute. He joined the team from the Cleveland Clinic where he was the director of the Lung Cancer Medical Oncology Program. Dr. Mekhail completed his medical degree at Cairo University in 1988, then went on to complete his medical training in the United Kingdom, where he earned fellowships of the Royal College of Surgeon of Edinburgh and Ireland. He completed his medical oncology fellowship at the Cleveland Clinic in Cleveland, Ohio. He is an associate professor at the University of Central Florida. Dr. Mekhail's extensive experience in the field of lung cancer is bolstered by his many awards, including being voted one of the Best Doctors in America in 2007-2008, 2008-2009 and 2009-2010.

Articles

Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS >= 1% (LEAP-007): A phase III, randomized, double-blind study

ANNALS OF ONCOLOGY

2021

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer A Phase 1/2 Open-label Nonrandomized Clinical Trial

JAMA ONCOLOGY

2021

Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy

Clinical lung cancer

2021

Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy

ANNALS OF ONCOLOGY

2021

Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors

ANNALS OF ONCOLOGY

2021

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

CANCER DISCOVERY

2021

Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study

SUPPORTIVE CARE IN CANCER

2020

Fat-Finding Mission: Primary Pleomorphic Liposarcoma of the Heart and Pericardium.

JACC. Case reports

2020

Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma

CLINICAL LUNG CANCER

2020

Updated results from a phase I/II study of mobocertinib (TAK788) in NSCLC with EGFR exon 20 insertions (exon20ins)

ANNALS OF ONCOLOGY

2020

Education & Training

Education

Cairo University Egypt

Residency

Cleveland Clinic Foundation Ohio

Fellowship

Cleveland Clinic Foundation Ohio

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT03829332

A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)

Icon for trial | MK7902-007 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score

The purpose of this study is to: Test the safety of the study drugs, lenvatinib and pembolizumab, when given together. See how well they work compared to pembrolizumab plus placebo (a lenvatinib look-alike with no active ingred ...

NCT03600883

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects with Advanced NSCLC with KRAS p.G12C Mutation

Icon for trial | 20170543 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subject

This study is currently enrolling.

This study will be conducted in 2 phases: Phase 1 and Phase 2. You will only participate in one phase of the study. The purpose of this Phase 1 study is to see at what dose of AMG 510 is recommended for participants to receive ...

NCT04129502

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Icon for trial | TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

This study is currently enrolling.

The purpose of this study is to determine how safe and how well TAK-788 works as an initial therapy in patients with NSCLC with EGFR exon 20 insertion mutations; the results in these patients will be compared with results in pa ...

NCT04035486

A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor EGFR Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)

Icon for trial | D5169C00001 A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor EGFR Mutation-Positive, Locally Advanced or Metastatic No

This study is currently enrolling.

AstraZeneca AB is doing this research to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for ...

NCT04956692

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Icon for trial | A86-00 A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Administered with Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants with

This study is currently enrolling.

This trial is testing pembrolizumab given as a shot under the skin (subcutaneously [SC]), to treat people with non–small–cell lung cancer (NSCLC). This trial will compare pembrolizumab SC to pembrolizumab given through a vein ( ...

NCT04892472

EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Icon for trial | EF-36 EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

This study is currently enrolling.

This study involves collecting data on the clinical results of an experimental device, the NovoTTF-200T, concomitant with a standard immunotherapy agent, pembrolizumab, for a first line treatment of your lung cancer. Tumor Tre ...

NCT04026412

A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Icon for trial | CA209-73L A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Duravalumab in Previously Untreated, Loc

This study is currently enrolling.

The purpose of this study is to evaluate the effectiveness (how well the drug(s) work), safety, and tolerability of adding the investigational drug, Nivolumab, to concurrent chemoradiotherapy followed by treatment with Nivoluma ...

NCT02367781

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non−Small Cell Lung Cancer

Icon for trial | GO29537 A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of MPDl3280A (Anti−PD-L1 Antibody) In Combination with Carboplatin and Nab-Paclitaxel for Chemotherapy-Naïve Patients with Stage IV Non-Squamous N

This study is currently enrolling.

[Abbreviated - Closed] The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and the specific type of lung cancer (non−small cell lung cancer [NSCLC]) from which you are suffering. MPDL3280A is a ...

NCT4913220

A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

Icon for trial | ACT16845 A Phase 1/2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with cemiplimab for the treatment of participants with advanced unresectable or metastatic skin cancers

This study is currently enrolling.

The purpose of the study is to determine the antitumor activity of SAR444245 for the treatment of either advanced melanoma or cutaneous squamous cell carcinoma (CSCC) when it is administered along with another anticancer therap ...